Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 17/20 | 0.47 |
| ▸ | MC3R | P41968 | 8/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.47 |
| ▸ | MC5R | P33032 | 1/20 | 0.47 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.43 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.43 |
| ▸ | MC1R | Q01726 | 3/20 | 0.41 |
| ▸ | TACR3 | P29371 | 1/20 | 0.38 |
| ▸ | PRCP | P42785 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13493139 | 0.90 | MC4R (0.48) | MC4RMC3RKCNH2MC5RMC1R | |
| SCHEMBL1947427 | 0.84 | MC4R (0.46) | MC4RMC3RKCNH2MC5RDPP4 | |
| SCHEMBL12536997 | 0.82 | TACR3 (0.45) | MC4RMC3RMC1RTACR3PRCP | |
| SCHEMBL12536991 | 0.82 | MC4R (0.43) | MC4RMC3RKCNH2MC5RMC1R | |
| SCHEMBL12536993 | 0.81 | TACR3 (0.43) | MC4RMC3RKCNH2MC5RMC1R | |
| SCHEMBL12536988 | 0.81 | MC4R (0.42) | MC4RMC3RKCNH2MC5RMC1R | |
| SCHEMBL29327394 | 0.80 | DPP4 (0.51) | MC4RMC3RKCNH2MC5RDPP4 | |
| SCHEMBL4615034 | 0.80 | DPP4 (0.51) | MC4RMC3RKCNH2MC5RDPP4 | |
| SCHEMBL12536970 | 0.79 | MC4R (0.62) | MC4RMC3RKCNH2MC5RDPP4 | |
| SCHEMBL12537027 | 0.78 | MC4R (0.56) | MC4RMC3RKCNH2MC5RMC1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110136814-A1 | Diazepine and Diazocane Compounds As MC4 Agonists | ANDREWS MARK DAVID | 2011-06-09 | — | — | US | disclosed |
| US-20110136814-A1 | Diazepine and Diazocane Compounds As MC4 Agonists | ANDREWS MARK DAVID | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136814-A1 | Diazepine and Diazocane Compounds As MC4 Agonists | MC4R, CHRM4, GPR4 | MC4R 1/4885MC3R 16/4885KCNH2 469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.